Wzorek

Laura A. Wzorek, Ph.D.

Associate
Registered Patent Attorney
Boston

I work with clients to protect their inventions in the pharmaceutical, chemical, and biotechnology industries.

Leveraging her research experience in organic chemistry, Dr. Laura Wzorek provides patent portfolio counseling in the areas of pharmaceuticals, chemistry, materials science, and biotechnology.

In particular, Laura works with clients to develop patent portfolio strategies, and prepares and prosecutes U.S. and foreign patent applications focused on small molecule pharmaceuticals, polymorphs, pharmaceutical formulations, therapeutic uses, synthetic methods, and materials science. She has also assisted in freedom-to-operate and patentability analyses.

Laura’s doctoral studies focused on asymmetric organometallic catalysis in the laboratory of Professor James Morken at Boston College.

Education

  • Boston University School of Law, J.D., 2019
  • Boston College, Ph.D. in Organic Chemistry, 2011
  • University of California, Berkeley, B.S. in Chemistry, 2006

Bar and Court Admissions

BAR ADMISSIONS
  • Massachusetts
COURT ADMISSIONS
  • U.S. Patent & Trademark Office (Agency)

Experience

  • Patent prosecution counsel for a variety of pharmaceutical companies, universities, and venture-backed research institutions. A list of representative patents obtained and patent applications drafted is shown below:
    • Small molecule pharmaceuticals:
      • Heterocyclic Glutaminase Inhibitors (US 10793535)
      • Substituted Amino Triazoles Useful as Human Chitinase Inhibitors (US 9944624)
      • Oral Complement Factor D Inhibitors (WO 2021/072198)
    • Polymorphs:
      • Crystal Forms of Glutaminase Inhibitors (US 10316030)
      • Crystalline Salt Forms of BOC-D-Arg-DMT-Lys-(Boc)-Phe-NH2 (US 11034724)
      • Crystalline Bis- and Tri-Hydrochloride Salt of Elamipretide (US 10676506)
    • Therapeutic Methods:
      • Combination Therapy with Gluatminase Inhibitors and Immuno-Oncology Agents (US 10258619)
      • Genotype-Agnostic Rescue of Cystic Fibrosis with Small Molecule Biocarbonate Channels (WO 2019/075214)
    • Synthetic Methods:
      • N-Carboxyanhydride-Based-Scale Synthesis of Elamipretide (US 10961273)
  • Successfully appealed to the USPTO Patent Trial and Appeal Board (PTAB) an obviousness-type double patenting rejection of claims to a Phase II drug candidate for the treatment of cancer.

Publications

  • Le, H., Kyne, R. E., Brozek, L. A., Morken, J. P., “Catalytic enantioselective allyl-allyl cross-coupling with a borylated allylboronate” Organic Letters 2013, 15, 1432.
  • Brozek, L. A., Ardolino, M. J., Morken, J. P., "Diastereocontrol in Asymmetric Allyl-Allyl Cross Coupling: Stereocontrolled Reaction of Prochiral Allylboronates with Prochiral Allyl Chlorides," Journal of the American Chemical Society 2011, 133, 16778. 
  • Brozek, L. A., Sieber, J. D., Morken, J. P., "Catalytic Enantioselective Conjugate Allylation of Unsaturated Methylidene Ketones," Organic Letters 2011, 13, 995. 
  • Zhang, P., Brozek, L. A., Morken, J. P., "Enantioselective Pd-Catalyzed Allyl-Allyl Cross Coupling," Journal of the American Chemical Society 2010, 132, 10686. Highlighted as "Synfact of the Month" by the journal Synfacts, November 2010. 

Honors & Involvement

HONORS
  • Listed as a “Rising Star” in Intellectual Property Law, Super Lawyers'  Massachusetts Rising Stars: A Comprehensive Listing of the Best Young Lawyers in Massachusetts (2021-2022)
  • BPLA Writing Competition – First Place (2019)
  • Michael Fricklas and Donna Astion Prize in Intellectual Property and Entertainment Law – Boston University School of Law (2019)
  • LaMattina Fellowship, Boston College

Speaking Engagements

  • A Hatch-Waxman Review: What to Know About the Hatch-Waxman Act As It Turns 39+, Foley Hoag Webinar, October 2022
  • "Asymmetric Allyl-Allyl Coupling via 3,3′-Reductive Elimination of Allyl-Metal Complexes and Development of Diastereoselective Transformations," Oral presentation at 13th Annual JCF Fr├╝hjahrssymposium, N├╝rnberg, Germany, March 2011